1. Home
  2. FIHL vs VCEL Comparison

FIHL vs VCEL Comparison

Compare FIHL & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FIHL
  • VCEL
  • Stock Information
  • Founded
  • FIHL 2014
  • VCEL 1989
  • Country
  • FIHL Bermuda
  • VCEL United States
  • Employees
  • FIHL N/A
  • VCEL N/A
  • Industry
  • FIHL
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FIHL
  • VCEL Health Care
  • Exchange
  • FIHL Nasdaq
  • VCEL Nasdaq
  • Market Cap
  • FIHL 1.8B
  • VCEL 2.1B
  • IPO Year
  • FIHL 2023
  • VCEL 1997
  • Fundamental
  • Price
  • FIHL $15.72
  • VCEL $40.25
  • Analyst Decision
  • FIHL Hold
  • VCEL Strong Buy
  • Analyst Count
  • FIHL 7
  • VCEL 8
  • Target Price
  • FIHL $20.43
  • VCEL $62.00
  • AVG Volume (30 Days)
  • FIHL 825.5K
  • VCEL 476.9K
  • Earning Date
  • FIHL 08-13-2025
  • VCEL 07-31-2025
  • Dividend Yield
  • FIHL 2.51%
  • VCEL N/A
  • EPS Growth
  • FIHL N/A
  • VCEL 521.85
  • EPS
  • FIHL N/A
  • VCEL 0.05
  • Revenue
  • FIHL $2,558,400,000.00
  • VCEL $238,541,000.00
  • Revenue This Year
  • FIHL $18.84
  • VCEL $23.03
  • Revenue Next Year
  • FIHL $8.21
  • VCEL $24.52
  • P/E Ratio
  • FIHL N/A
  • VCEL $675.02
  • Revenue Growth
  • FIHL 23.93
  • VCEL 14.80
  • 52 Week Low
  • FIHL $14.17
  • VCEL $37.39
  • 52 Week High
  • FIHL $21.32
  • VCEL $63.00
  • Technical
  • Relative Strength Index (RSI)
  • FIHL 39.42
  • VCEL 44.06
  • Support Level
  • FIHL $15.75
  • VCEL $39.39
  • Resistance Level
  • FIHL $16.98
  • VCEL $42.61
  • Average True Range (ATR)
  • FIHL 0.40
  • VCEL 1.73
  • MACD
  • FIHL -0.03
  • VCEL -0.15
  • Stochastic Oscillator
  • FIHL 8.70
  • VCEL 24.16

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: